Tags

Type your tag names separated by a space and hit enter

Laropiprant plus niacin for dyslipidemia and prevention of cardiovascular disease.
Expert Opin Pharmacother. 2010 Jul; 11(10):1715-26.EO

Abstract

IMPORTANCE OF THE FIELD

Prevention of cardiovascular disease has been only partially successful with the use of cholesterol-lowering drugs like statins. There is a residual risk remaining, which may be addressed by increasing protective high-density lipoprotein (HDL) cholesterol and apolipoprotein A1. The best drug available for that purpose is niacin. In addition to increasing HDL cholesterol and apolipoprotein A1, niacin decreases triglycerides, low-density lipoprotein (LDL)-cholesterol and lipoprotein(a) and has been named the broad-spectrum lipid drug.

AREAS COVERED IN THIS REVIEW

This review summarizes to what extent a new formulation of niacin may meet this request. The effects of niacin on lipoproteins, atherosclerosis and cardiovascular disease are described, from its first publication in 1955, and also its mechanism of action on lipoproteins and on flushing. The flushing inhibitor laropiprant is described as well as the antiflushing effect of this compound when added to extended-release niacin.

WHAT THE READER WILL GAIN

The reader will gain knowledge of the development of niacin as an antiatherosclerosis treatment and of the added value that laropiprant may offer this treatment principle; and also the present place of niacin/laropiprant in the armamentarium of cardiovascular preventive drugs.

TAKE HOME MESSAGE

Niacin/laropiprant is a welcome means to address the residual risk in high-risk patients on statin therapy. However, the drug combination cannot completely eliminate niacin-induced side effects. Prescribing this treatment, therefore, will require careful provision of information and instruction to the patient.

Authors+Show Affiliations

Department of Medicine and Health, Linköping University, SE-58183 Linköping, Sweden. anders.olsson@liu.se

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

20518616

Citation

Olsson, Anders G.. "Laropiprant Plus Niacin for Dyslipidemia and Prevention of Cardiovascular Disease." Expert Opinion On Pharmacotherapy, vol. 11, no. 10, 2010, pp. 1715-26.
Olsson AG. Laropiprant plus niacin for dyslipidemia and prevention of cardiovascular disease. Expert Opin Pharmacother. 2010;11(10):1715-26.
Olsson, A. G. (2010). Laropiprant plus niacin for dyslipidemia and prevention of cardiovascular disease. Expert Opinion On Pharmacotherapy, 11(10), 1715-26. https://doi.org/10.1517/14656566.2010.489894
Olsson AG. Laropiprant Plus Niacin for Dyslipidemia and Prevention of Cardiovascular Disease. Expert Opin Pharmacother. 2010;11(10):1715-26. PubMed PMID: 20518616.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Laropiprant plus niacin for dyslipidemia and prevention of cardiovascular disease. A1 - Olsson,Anders G, PY - 2010/6/4/entrez PY - 2010/6/4/pubmed PY - 2010/8/3/medline SP - 1715 EP - 26 JF - Expert opinion on pharmacotherapy JO - Expert Opin Pharmacother VL - 11 IS - 10 N2 - IMPORTANCE OF THE FIELD: Prevention of cardiovascular disease has been only partially successful with the use of cholesterol-lowering drugs like statins. There is a residual risk remaining, which may be addressed by increasing protective high-density lipoprotein (HDL) cholesterol and apolipoprotein A1. The best drug available for that purpose is niacin. In addition to increasing HDL cholesterol and apolipoprotein A1, niacin decreases triglycerides, low-density lipoprotein (LDL)-cholesterol and lipoprotein(a) and has been named the broad-spectrum lipid drug. AREAS COVERED IN THIS REVIEW: This review summarizes to what extent a new formulation of niacin may meet this request. The effects of niacin on lipoproteins, atherosclerosis and cardiovascular disease are described, from its first publication in 1955, and also its mechanism of action on lipoproteins and on flushing. The flushing inhibitor laropiprant is described as well as the antiflushing effect of this compound when added to extended-release niacin. WHAT THE READER WILL GAIN: The reader will gain knowledge of the development of niacin as an antiatherosclerosis treatment and of the added value that laropiprant may offer this treatment principle; and also the present place of niacin/laropiprant in the armamentarium of cardiovascular preventive drugs. TAKE HOME MESSAGE: Niacin/laropiprant is a welcome means to address the residual risk in high-risk patients on statin therapy. However, the drug combination cannot completely eliminate niacin-induced side effects. Prescribing this treatment, therefore, will require careful provision of information and instruction to the patient. SN - 1744-7666 UR - https://www.unboundmedicine.com/medline/citation/20518616/Laropiprant_plus_niacin_for_dyslipidemia_and_prevention_of_cardiovascular_disease_ L2 - https://www.tandfonline.com/doi/full/10.1517/14656566.2010.489894 DB - PRIME DP - Unbound Medicine ER -